Insmed Inc

Insmed CEO Lewis William’s latest insider trades show a strategic re‑balance at a deep discount, signalling confidence in the company’s long‑term biopharma prospects.

Insmed insider trading: Chief Legal Officer Michael Smith’s recent buying and selling reveals a 26 % stake increase, signalling confidence amid a 13.6 % weekly rally.

Insmed CEO Lewis William’s recent 10b5‑1 buys signal fresh confidence in the drug company’s upside—read why insider activity may hint at a rally and what to watch for.

Insmed insider sales spike: Dr. Martina Flammer sells 869 shares under a 10b‑5‑1 plan, amid a 4.47% weekly dip and negative earnings—what this means for investors.

Insmed insider activity: CMO Martina Flammer sold 869 shares at $152.44, signaling routine portfolio moves amid modest market impact and potential near‑term shift.

Insmed CEO Lewis William’s Jan‑20 trades show disciplined buying lows and selling at rally highs—insight into insider confidence and liquidity strategy.

Insmed insider trading shows CEO Lewis William balancing large sales near $170 with strategic purchases at $30‑$17, signaling risk‑managed confidence amid biotech growth and volatility.